Flot.bio x Philip Hemme cover image

Alex Zhavoronkov, Insilico Medicine | AI Drug Development, Longevity | E39

Flot.bio x Philip Hemme

00:00

Building a Pipeline and IPF Phase 2A Success

Why Insilico moved from services to developing its own assets, nominating many candidates, and the IPF program: AI-identified target, de novo molecules, and positive phase 2A results.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app